Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.54 |
| ▸ | CA1 | P00915 | 5/20 | 0.54 |
| ▸ | CA2 | P00918 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2332550 | 0.74 | ESR1 (0.60) | TSHRCYP19A1ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL9609212 | 0.74 | MAPT (0.57) | TSHRCA1CA2ALDH1A1CYP2C9 | |
| SCHEMBL9052961 | 0.73 | CA1 (0.71) | CYP19A1CA1CA2ALDH1A1CYP1A2 | |
| SCHEMBL3822070 | 0.72 | ALDH1A1 (0.67) | CYP19A1CA1CA2ALDH1A1CYP1A2 | |
| SCHEMBL2332170 | 0.71 | CA1 (0.47) | TSHRCA1CA2ALDH1A1KMT2A | |
| SCHEMBL29482680 | 0.71 | CA1 (0.71) | CYP19A1CA1CA2ALDH1A1CYP1A2 | |
| SCHEMBL3810768 | 0.70 | CYP19A1 (0.86) | CYP19A1CA1CA2ALDH1A1CYP1A2 | |
| SCHEMBL3813366 | 0.70 | CYP19A1 (1.00) | CYP19A1CA1CA2ALDH1A1CYP1A2 | |
| SCHEMBL13692850 | 0.70 | MAPT (0.80) | TSHRCA1CA2ALDH1A1CYP1A2 | |
| SCHEMBL3204569 | 0.70 | ALDH1A1 (1.00) | TSHRCYP19A1CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9717706-B2 | Chromone inhibitors of S-nitrosoglutathione reductase | NIVALIS THERAPEUTICS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20150352073-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC | 2015-12-10 | — | — | US | disclosed |
| US-20140163092-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2533637-B1 | CHROMONE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS INC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8669381-B2 | Chromone inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130274320-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | NIVALIS THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8481590-B2 | Chromone inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2533637-A1 | CHROMONE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120295966-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2011099978-A1 | CHROMONE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352073-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | POR, GSR, CBR1 | TSHR 887/4885CYP19A1 125/4885CA1 4255/4885 |
| US-20130274320-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | POR, GSR, CBR1 | TSHR 887/4885CYP19A1 125/4885CA1 4255/4885 |
| US-20140163092-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | POR, GSR, CBR1 | TSHR 887/4885CYP19A1 125/4885CA1 4255/4885 |
| US-20120295966-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | POR, GSR, CBR1 | TSHR 887/4885CYP19A1 125/4885CA1 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.